Equillium (FRA:0FY) Debt-to-Revenue : 0.02 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Equillium Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Equillium's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.40 Mil. Equillium's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.35 Mil. Equillium's annualized Revenue for the quarter that ended in Dec. 2023 was €33.78 Mil. Equillium's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.02.

Equillium Debt-to-Revenue Historical Data

The historical data trend for Equillium's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Equillium Debt-to-Revenue Chart

Equillium Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

N/A

0.65

0.02

Equillium Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial															0.16	0.24	0.03	0.03	0.02

Competitive Comparison of Equillium's Debt-to-Revenue

For the Biotechnology subindustry, Equillium's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Equillium's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Equillium's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Equillium's Debt-to-Revenue falls into.

Equillium Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Equillium's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.403	+	0.352)	/	33.089
	=	0.02

Equillium's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.403	+	0.352)	/	33.784
	=	0.02

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.

Equillium Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Equillium's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Equillium (FRA:0FY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (FRA:0FY) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

EQ:USA 0FY:Germany

Address

2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037

Website

https://www.equilliumbio.com

Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Equillium (FRA:0FY) Headlines

No Headlines